MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
基本信息
- 批准号:6797835
- 负责人:
- 金额:$ 789.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-04 至 2008-02-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research (MRCE) is a consortium of leading Midwest institutions that will serve the biodefense research and training needs for Region VII as well as parts of Ohio. The founding members of the MRCE are Washington University in St. Louis (site of the Administrative Core), Case Western Reserve University, St. Louis University, the Midwest Research Institute, and the University of Missouri. The major objective of the MRCE is to harness outstanding scientists from the best institutions to focus on critical clinical issues in biodefense and emerging infectious diseases. Our goal is research that will have an immediate impact on the nation's public health, and will provide the scientific base for a strong biodefense effort. The Strategic Plan for the MRCE centers on a comprehensive multi-institutional effort on the biology of poxviruses. The conjunction of extraordinarily strong existing programs in clinical research on smallpox vaccination and basic research on poxviruses and innate immunity to viral infections will allow us to answer the critical questions about the biology of vaccinia infection, and the risks of smallpox vaccination. Our second program (the developmental projects) focuses on plague, and will use state-of-the-art platforms in genetics and structural biology to study the pathogenesis of Yersinia pestis and design a new class of antibacterial agents, the pilicides, for the treatment of plague. The backbone of the MRCE effort is Core facilities designed to serve the biodefense needs of Region VII and the nation. Foremost among the Cores is the Washington University Genome Sequencing Center, the largest sequencing center in the United States. The MRCE Strategic Plan will consolidate the high throughput sequencing and genotyping services for all the Regional Centers for Excellence at the MRCE, resulting in significant cost savings. Finally, the MRCE will lead the effort to recruit new investigators to clinical and basic research in biodefense and train them in how to conduct this research safely and securely through three distinct Career Development Programs, including a one-of-a-kind fellowship program that will train postdoctoral fellows in the life sciences to become biosafety officers. The MRCE is uniquely positioned to serve Region VII and the nation through an exceptional program that addresses the most immediate and urgent national biodefense needs.
描述(由申请人提供):中西部地区生物防御和新兴传染病研究卓越中心 (MRCE) 是一个由中西部领先机构组成的联盟,旨在满足第七区以及俄亥俄州部分地区的生物防御研究和培训需求。 MRCE 的创始成员包括圣路易斯华盛顿大学(行政核心所在地)、凯斯西储大学、圣路易斯大学、中西部研究所和密苏里大学。 MRCE 的主要目标是利用来自最好机构的杰出科学家专注于生物防御和新出现的传染病方面的关键临床问题。 我们的目标是对国家公共卫生产生直接影响的研究,并将为强大的生物防御工作提供科学基础。 MRCE 的战略计划以痘病毒生物学方面的综合性多机构努力为中心。 天花疫苗接种临床研究与痘病毒和病毒感染先天免疫的基础研究相结合,使我们能够回答有关痘苗感染的生物学以及天花疫苗接种风险的关键问题。 我们的第二个项目(开发项目)重点关注鼠疫,并将利用最先进的遗传学和结构生物学平台来研究鼠疫耶尔森氏菌的发病机制,并设计一类新型抗菌剂——pilicides,用于治疗瘟疫。 MRCE 工作的支柱是旨在满足第七区和国家生物防御需求的核心设施。其中最重要的是华盛顿大学基因组测序中心,它是美国最大的测序中心。 MRCE 战略计划将整合 MRCE 所有区域卓越中心的高通量测序和基因分型服务,从而显着节省成本。 最后,MRCE 将牵头招募新的研究人员进行生物防御的临床和基础研究,并培训他们如何通过三个不同的职业发展计划安全可靠地进行这项研究,其中包括一项独一无二的奖学金计划,将培训生命科学领域的博士后成为生物安全官员。 MRCE 具有独特的优势,可以通过一项特殊计划为第七区和国家服务,解决最紧迫的国家生物防御需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAMUEL L. STANLEY其他文献
SAMUEL L. STANLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAMUEL L. STANLEY', 18)}}的其他基金
An Animal Biosafety Level 3 Laboratory for Stony Brook University
石溪大学动物生物安全三级实验室
- 批准号:
7872073 - 财政年份:2010
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases (Development Projects)
生物防御和新发传染病 MRCE(开发项目)
- 批准号:
7641692 - 财政年份:2008
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
- 批准号:
7207962 - 财政年份:2003
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
- 批准号:
6908968 - 财政年份:2003
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
- 批准号:
7594903 - 财政年份:2003
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
- 批准号:
7020077 - 财政年份:2003
- 资助金额:
$ 789.41万 - 项目类别:
MRCE for Biodefense and Emerging Infectious Diseases
生物防御和新发传染病的 MRCE
- 批准号:
6698909 - 财政年份:2003
- 资助金额:
$ 789.41万 - 项目类别:
相似海外基金
Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
炭疽、鼠疫和兔热病药物的发现和临床前开发
- 批准号:
7485731 - 财政年份:2006
- 资助金额:
$ 789.41万 - 项目类别:
Multiplexed POC Diagnostic System for Bio-Threat Agents
生物威胁因子多重 POC 诊断系统
- 批准号:
7009717 - 财政年份:2005
- 资助金额:
$ 789.41万 - 项目类别:
A Rapid, Sensitive and Fully Automated Y. pestis Test
快速、灵敏且全自动的鼠疫耶尔森氏菌测试
- 批准号:
6887444 - 财政年份:2004
- 资助金额:
$ 789.41万 - 项目类别:
The Role of LPS and Toll-like Receptors in Plague
LPS 和 Toll 样受体在鼠疫中的作用
- 批准号:
7021459 - 财政年份:2004
- 资助金额:
$ 789.41万 - 项目类别:
Development of ProtollinTM Plague Vaccine
ProtollinTM鼠疫疫苗的研制
- 批准号:
6845743 - 财政年份:2004
- 资助金额:
$ 789.41万 - 项目类别: